FY24 Appropriations Research & Public Health Programs
FY24 Defense Appropriations
FY24 HHS/DoD Approps
Access to Disability Benefits w/Pulmonary Hypertension
COPD Oxygen Access
Patient-focused drug development @ FDA
Healthcare Reform Patient Protections
H.R.830 - HELP Copays Act
S.652 - Safe Step Act
Duration: January 1, 2008
to
present
General Issues: Budget/Appropriations , Health Issues
Spending: about $46,500 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, Centers For Disease Control & Prevention (CDC), Natl Institutes of Health (NIH), Social Security Administration (SSA), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
Health and Medicine Counsel, LLC amended a lobbying report for representation of PULMONARY HYPERTENSION ASSOCIATION in Q12024 on April 16.
Original Filing: 301550965.xml
Lobbying Issues
FY24 Appropriations Research & Public Health Programs
FY24 Defense Appropriations
FY24 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
COPD Oxygen Access
Patient-focused drug development @ FDA
Healthcare Reform Patient Protections
H.R.830 - HELP Copays Act
S.652 - Safe Step Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
1st Quarter, 2024
In Q1, Health and Medicine Counsel, LLC lobbied for PULMONARY HYPERTENSION ASSOCIATION , earning $10,000. The report was filed on April 4.
Original Filing: 301546493.xml
Lobbying Issues
FY24 Appropriations Research & Public Health Programs
FY24 Defense Appropriations
FY24 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
COPD Oxygen Access
Patient-focused drug development @ FDA
Healthcare Reform Patient Protections
H.R.830 - HELP Copays Act
S.652 - Safe Step Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2023
Health and Medicine Counsel, LLC amended a lobbying report for representation of PULMONARY HYPERTENSION ASSOCIATION in Q42023 on April 17.
Original Filing: 301551810.xml
Lobbying Issues
FY24 Appropriations Research & Public Health Programs
FY24 Defense Appropriations
FY24 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
COPD Oxygen Access
Patient-focused drug development @ FDA
Healthcare Reform Patient Protections
H.R.830 - HELP Copays Act
S.652 - Safe Step Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2023
In Q4, Health and Medicine Counsel, LLC lobbied for PULMONARY HYPERTENSION ASSOCIATION , earning $10,000. The report was filed on Jan. 3.
Original Filing: 301521501.xml
Lobbying Issues
FY24 Appropriations Research & Public Health Programs
FY24 Defense Appropriations
FY24 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
COPD Oxygen Access
Patient-focused drug development @ FDA
Healthcare Reform Patient Protections
H.R.830 - HELP Copays Act
S.652 - Safe Step Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2023
Health and Medicine Counsel, LLC amended a lobbying report for representation of PULMONARY HYPERTENSION ASSOCIATION in Q32023 on April 17.
Original Filing: 301551918.xml
Lobbying Issues
FY24 Appropriations Research & Public Health Programs
FY24 Defense Appropriations
FY24 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
COPD Oxygen Access
Patient-focused drug development @ FDA
Healthcare Reform Patient Protections
H.R.830 - HELP Copays Act
S.652 - Safe Step Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2023
In Q3, Health and Medicine Counsel, LLC lobbied for PULMONARY HYPERTENSION ASSOCIATION , earning $10,000. The report was filed on Oct. 16, 2023.
Original Filing: 301501082.xml
Lobbying Issues
FY24 Appropriations Research & Public Health Programs
FY24 Defense Appropriations
FY24 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
COPD Oxygen Access
Patient-focused drug development @ FDA
Healthcare Reform Patient Protections
H.R.830 - HELP Copays Act
S.652 - Safe Step Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
2nd Quarter, 2023
In Q2, Health and Medicine Counsel, LLC lobbied for PULMONARY HYPERTENSION ASSOCIATION , earning $10,000. The report was filed on July 14, 2023.
Original Filing: 301476059.xml
Lobbying Issues
FY24 Appropriations Research & Public Health Programs
FY24 Defense Appropriations
FY24 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
COPD Oxygen Access
Patient-focused drug development @ FDA
Healthcare Reform Patient Protections
H.R.830 - HELP Copays Act
S.652 - Safe Step Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
1st Quarter, 2023
In Q1, Health and Medicine Counsel, LLC lobbied for PULMONARY HYPERTENSION ASSOCIATION , earning $6,500. The report was filed on April 11, 2023.
Original Filing: 301450232.xml
Lobbying Issues
FY24 Appropriations Research & Public Health Programs
FY24 Defense Appropriations
FY24 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
COPD Oxygen Access
Patient-focused drug development @ FDA
Healthcare Reform Patient Protections
H.R.830 - HELP Copays Act
S.652 - Safe Step Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2022
In Q4, Health and Medicine Counsel, LLC lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 1, 2023.
Original Filing: 301424408.xml
Lobbying Issues
FY22 Appropriations Research & Public Health Programs
FY22 Defense Appropriations
FY22 HHS/DoD Approps
COVID-19 Supplemental Appropriations
COVID-19 Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
COVID-19 Relief Packages
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2022
In Q3, Health and Medicine Counsel, LLC lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 5, 2022.
Original Filing: 301401415.xml
Lobbying Issues
FY22 Appropriations Research & Public Health Programs
FY22 Defense Appropriations
FY22 HHS/DoD Approps
COVID-19 Supplemental Appropriations
COVID-19 Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
COVID-19 Relief Packages
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
2nd Quarter, 2022
In Q2, Health and Medicine Counsel, LLC lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 12, 2022.
Original Filing: 301378956.xml
Lobbying Issues
FY22 Appropriations Research & Public Health Programs
FY22 Defense Appropriations
FY22 HHS/DoD Approps
COVID-19 Supplemental Appropriations
COVID-19 Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
COVID-19 Relief Packages
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
1st Quarter, 2022
In Q1, Health and Medicine Counsel, LLC lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 14, 2022.
Original Filing: 301356109.xml
Lobbying Issues
FY22 Appropriations Research & Public Health Programs
FY22 Defense Appropriations
FY22 HHS/DoD Approps
COVID-19 Supplemental Appropriations
COVID-19 Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
COVID-19 Relief Packages
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2021
In Q4, Health and Medicine Counsel, LLC lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 12, 2022.
Original Filing: 301321698.xml
Lobbying Issues
FY22 Appropriations Research & Public Health Programs
FY22 Defense Appropriations
FY22 HHS/DoD Approps
COVID-19 Supplemental Appropriations
COVID-19 Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
COVID-19 Relief Packages
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2021
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 4, 2021.
Original Filing: 301296440.xml
Lobbying Issues
FY22 Appropriations Research & Public Health Programs
FY22 Defense Appropriations
FY22 HHS/DoD Approps
COVID-19 Supplemental Appropriations
COVID-19 Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
COVID-19 Relief Packages
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
2nd Quarter, 2021
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 7, 2021.
Original Filing: 301273897.xml
Lobbying Issues
FY22 Appropriations Research & Public Health Programs
FY22 Defense Appropriations
FY22 HHS/DoD Approps
COVID-19 Supplemental Appropriations
COVID-19 Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
COVID-19 Relief Packages
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
1st Quarter, 2021
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 7, 2021.
Original Filing: 301251128.xml
Lobbying Issues
FY22 Appropriations Research & Public Health Programs
FY22 Defense Appropriations
FY22 HHS/DoD Approps
COVID-19 Supplemental Appropriations
COVID-19 Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
COVID-19 Relief Packages
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2020
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 7, 2021.
Original Filing: 301229074.xml
Lobbying Issues
FY20 & 21 Appropriations Research & Public Health Programs
FY20 & 21 Defense Appropriations
FY20 & 21 HHS/DoD Approps
COVID-19 Supplemental Appropriations
COVID-19 Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
COVID-19 Relief Packages
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2020
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 8, 2020.
Original Filing: 301208084.xml
Lobbying Issues
FY20 & 21 Appropriations Research & Public Health Programs
FY20 & 21 Defense Appropriations
FY20 & 21 HHS/DoD Approps
COVID-19 Supplemental Appropriations
COVID-19 Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
COVID-19 Relief Packages
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
2nd Quarter, 2020
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 14, 2020.
Original Filing: 301187817.xml
Lobbying Issues
FY20 & 21 Appropriations Research & Public Health Programs
FY20 & 21 Defense Appropriations
FY20 & 21 HHS/DoD Approps
COVID-19 Supplemental Appropriations
COVID-19 Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
COVID-19 Relief Packages
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
1st Quarter, 2020
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 9, 2020.
Original Filing: 301154915.xml
Lobbying Issues
FY20 & 21 Appropriations Research & Public Health Programs
FY20 & 21 Defense Appropriations
FY20 & 21 HHS/DoD Approps
COVID-19 Supplemental Appropriations
COVID-19 Legislation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
COVID-19 Relief Packages
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2019
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 15, 2020.
Original Filing: 301105800.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
FY18 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2019
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 4, 2019.
Original Filing: 301063305.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
FY18 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
2nd Quarter, 2019
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 9, 2019.
Original Filing: 301043693.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
FY18 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
1st Quarter, 2019
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 22, 2019.
Original Filing: 301033251.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
FY18 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2018
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 7, 2019.
Original Filing: 301002501.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
FY18 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2018
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 10, 2018.
Original Filing: 300983950.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
FY18 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
2nd Quarter, 2018
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 11, 2018.
Original Filing: 300963614.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
FY18 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
1st Quarter, 2018
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 11, 2018.
Original Filing: 300943553.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
FY18 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2017
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 10, 2018.
Original Filing: 300922241.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
FY18 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2017
HEALTH AND MEDICINE COUNSEL OF WASHINGTON amended a lobbying report for representation of PULMONARY HYPERTENSION ASSOCIATION in Q42017 on Jan. 10, 2018.
Original Filing: 300922253.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
FY18 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2017
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 6, 2017.
Original Filing: 300901710.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
FY18 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
2nd Quarter, 2017
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 11, 2017.
Original Filing: 300883188.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
FY18 HHS/DoD Approps
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
Access to Marketplace Insurance
Healthcare Reform Patient Protections
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
1st Quarter, 2017
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 11, 2017.
Original Filing: 300863936.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Patients' Access to Treatments Act
HR 3742: Access to Marketplace Insurance Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2016
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 6, 2017.
Original Filing: 300843964.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Pulmonary Hypertension Research & Diagnosis Act, H.R. 3520
Patients' Access to Treatments Act
21st Century Cures Initiatives
HR 3742: Access to Marketplace Insurance Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2016
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 14, 2016.
Original Filing: 300827773.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Pulmonary Hypertension Research & Diagnosis Act, H.R. 3520
Patients' Access to Treatments Act
21st Century Cures Initiatives
HR 3742: Access to Marketplace Insurance Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
2nd Quarter, 2016
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 13, 2016.
Original Filing: 300808847.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Pulmonary Hypertension Research & Diagnosis Act, H.R. 3520
Patients' Access to Treatments Act
21st Century Cures Initiatives
HR 3742: Access to Marketplace Insurance Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
1st Quarter, 2016
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 6, 2016.
Original Filing: 300788607.xml
Lobbying Issues
FY17 Appropriations Research & Public Health Programs
FY17 Defense Appropriations
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Pulmonary Hypertension Research & Diagnosis Act, H.R. 3520
Patients' Access to Treatments Act
21st Century Cures Initiatives
HR 3742: Access to Marketplace Insurance Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2015
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 14, 2016.
Original Filing: 300771542.xml
Lobbying Issues
House & Senate FY15 & FY16 L-HHS Appropriations (Biomedical Research & Public Health Programs)
Deficit Reduction & Sequestration
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Pulmonary Hypertension Research & Diagnosis Act, H.R. 3520
Patients' Access to Treatments Act
21st Century Cures Initiatives
HR 3742: Access to Marketplace Insurance Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2015
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 14, 2015.
Original Filing: 300752882.xml
Lobbying Issues
House & Senate FY15 & FY16 L-HHS Appropriations (Biomedical Research & Public Health Programs)
Deficit Reduction & Sequestration
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Pulmonary Hypertension Research & Diagnosis Act, H.R. 3520
Patients' Access to Treatments Act
21st Century Cures Initiatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
2nd Quarter, 2015
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 10, 2015.
Original Filing: 300732987.xml
Lobbying Issues
House & Senate FY15 & FY16 L-HHS Appropriations (Biomedical Research & Public Health Programs)
Deficit Reduction & Sequestration
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Pulmonary Hypertension Research & Diagnosis Act
Patients' Access to Treatments Act
21st Century Cures Initiatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
1st Quarter, 2015
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 13, 2015.
Original Filing: 300714339.xml
Lobbying Issues
House & Senate FY15 & FY16 L-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
Deficit Reduction & Sequestration
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
Pulmonary Hypertension Research & Diagnosis Act
Patients' Access to Treatments Act
21st Century Cures Initiatives
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2014
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 13, 2015.
Original Filing: 300694458.xml
Lobbying Issues
House & Senate FY14 &15 L-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
Deficit Reduction & Sequestration
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
H.R. 2073 & S 1453: Pulmonary Hypertension Research & Diagnosis Act
H.R. 460: Patients' Access to Treatments Act
H.R. 3114: MODDERN Cures Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2014
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 8, 2014.
Original Filing: 300674321.xml
Lobbying Issues
House & Senate FY14 & FY15 L-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
Deficit Reduction & Sequestration
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDA
H.R. 2073 & S 1453: Pulmonary Hypertension Research & Diagnosis Act
H.R. 460: Patients' Access to Treatments Act
H.R. 3114: MODDERN Cures Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
2nd Quarter, 2014
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 8, 2014.
Original Filing: 300661649.xml
Lobbying Issues
House & Senate FY14 &15 L-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
Deficit Reduction & Sequestration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDAH.R. 2073 & S 1453: Pulmonary Hypertension Research & Diagnosis Act
H.R. 460: Patients' Access to Treatments Act
H.R. 3114: MODDERN Cures Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
1st Quarter, 2014
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 14, 2014.
Original Filing: 300635204.xml
Lobbying Issues
House & Senate FY14 &15 L-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
Deficit Reduction & Sequestration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDAH.R. 2073 & S 1453: Pulmonary Hypertension Research & Diagnosis Act
H.R. 460: Patients' Access to Treatments Act
H.R. 3114: MODDERN Cures Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2013
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 9, 2014.
Original Filing: 300612111.xml
Lobbying Issues
House & Senate FY13&14 L-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
Deficit Reduction & Sequestration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDAH.R. 2073 & S 1453: Pulmonary Hypertension Research & Diagnosis Act
H.R. 460: Patients' Access to Treatments Act
H.R. 3114: MODDERN Cures Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2013
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 9, 2013.
Original Filing: 300591568.xml
Lobbying Issues
House & Senate FY13&14 L-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
Deficit Reduction & Sequestration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDAH.R. 2073: Pulmonary Hypertension Research & Diagnosis Act
Senate Pulmonary Hypertension Legislation
H.R. 460: Patients' Access to Treatments Act
H.R. 3114: MODDERN Cures Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
2nd Quarter, 2013
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 12, 2013.
Original Filing: 300571048.xml
Lobbying Issues
House & Senate FY13&14 L-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
Deficit Reduction & Sequestration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Patient-focused drug development @ FDAH.R. 2073: Pulmonary Hypertension Research & Diagnosis Act
Senate Pulmonary Hypertension Legislation
H.R. 460: Patients' Access to Treatments Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
1st Quarter, 2013
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 17, 2013.
Original Filing: 300551609.xml
Lobbying Issues
House & Senate FY13 L-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
Deficit Reduction & Sequestration
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Access to Disability Benefits w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDCH.R. 460: Patients' Access to Treatments Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
4th Quarter, 2012
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 16, 2013.
Original Filing: 300529810.xml
Lobbying Issues
House & Senate FY13 L-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 775 & H.R. 1810: Tom Lantos Pulmonary Hypertension Research & Education Act
Access to Disability Benefits for Patients w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDCH.R. 4209: Patient Access to Treatments Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
3rd Quarter, 2012
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 17, 2012.
Original Filing: 300508524.xml
Lobbying Issues
House & Senate FY13 L-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 775 & H.R. 1810: Tom Lantos Pulmonary Hypertension Research & Education Act
Access to Disability Benefits for Patients w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH) Social Security Administration (SSA)
2nd Quarter, 2012
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 17, 2012.
Original Filing: 300486031.xml
Lobbying Issues
House & Senate FY13 Labor-HHS-Appropriations (Biomedical Research & Disease Prevention Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 775 & H.R. 1810: Tom Lantos Pulmonary Hypertension Research & Education Act
Access to Disability Benefits for Patients w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH)
1st Quarter, 2012
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 4, 2012.
Original Filing: 300457667.xml
Lobbying Issues
House & Senate FY13 Labor-HHS-Appropriations (Biomedical Research & Disease Prevention Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 775 & H.R. 1810: Tom Lantos Pulmonary Hypertension Research & Education Act
Access to Disability Benefits for Patients w/Pulmonary Hypertension
Pulmonary Hypertension Research activities at NIH
Pulmonary Hypertension education & awareness activities at CDC
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Natl Institutes of Health (NIH)
4th Quarter, 2011
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 5, 2012.
Original Filing: 300434703.xml
Lobbying Issues
House & Senate FY13 Labor-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
House & Senate FY13 Defense Appropriations (Biomedical Research Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S 775 & HR 1810: Tom Lantos Pulmonary Hypertension Research and Education Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 13, 2011.
Original Filing: 300413353.xml
Lobbying Issues
House & Senate FY12 Labor-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
HR 1473: Department of Defense and Full Year Continuing Appropriations Act (HHS programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S 775 & HR 1810: Tom Lantos Pulmonary Hypertension Research and Education Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH)
2nd Quarter, 2011
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 13, 2011.
Original Filing: 300389208.xml
Lobbying Issues
House & Senate FY12 Labor-HHS Appropriations (Biomedical Research & Disease Prevention Programs)
HR 1473: Department of Defense and Full Year Continuing Appropriations Act (HHS programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S 775 / HR 1810: Tom Lantos Pulmonary Hypertension Research and Education Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH)
1st Quarter, 2011
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 20, 2011.
Original Filing: 300376056.xml
Lobbying Issues
House and Senate FY11& FY12 Labor-HHS Appropriations (Biomedical Research and Disease Prevention Programs)
H.R. 1: FY11 Appropriations Continuing Resolution
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Pulmonary Hypertension Research and Education Act
Pulmonary Hypertension Research at NIH
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH)
4th Quarter, 2010
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 20, 2011.
Original Filing: 300349388.xml
Lobbying Issues
House and Senate FY11 Labor-HHS Appropriations Bills (Biomedical Research and Disease Prevention Programs)
House and Senate FY11 DoD Appropriations Bills (Peer Reviewed Medical Research Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 1030 & S 2803: Tom Lantos Pulmonary Hypertension Research and Education Act
Pulmonary Hypertension Research at NIH
Agencies Lobbied
Natl Institutes of Health (NIH) U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 8, 2010.
Original Filing: 300310065.xml
Lobbying Issues
House and Senate FY11 Labor-HHS Appropriations Bills (Biomedical Research and Disease Prevention Programs)
House and Senate FY11 DoD Appropriations Bills (Peer Reviewed Medical Research Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 1030 & S 2803: Tom Lantos Pulmonary Hypertension Research and Education Act
Pulmonary Hypertension Research at NIH
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH)
2nd Quarter, 2010
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 16, 2010.
Original Filing: 300288588.xml
Lobbying Issues
House and Senate FY11 Labor-HHS Appropriations Bills (Biomedical Research and Disease Prevention Programs)
House and Senate FY11 DoD Appropriations Bills (Peer Reviewed Medical Research Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 1030 & S 2803: Tom Lantos Pulmonary Hypertension Research and Education Act
Pulmonary Hypertension Research at NIH
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH)
1st Quarter, 2010
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 20, 2010.
Original Filing: 300268301.xml
Lobbying Issues
House and Senate FY11 Labor-HHS Appropriations Bills (Biomedical Research and Disease Prevention Programs)
House and Senate FY11 DoD Appropriations Bills (Peer Reviewed Medical Research Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1030 & S. 2803: Tom Lantos Pulmonary Hypertension Research and Education Act
Pulmonary Hypertension Research at NIH
H.R. 3590: Patient Protection and Affordable Care Act (pre-existing condition exclusion elimination, lifetime and annual benefit cap
elimination, Cures Acceleration Network establishment, coverage of clinical trials)H.R. 4872: Reconciliation Act of 2010 (lifetime and annual cap elimination)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH)
4th Quarter, 2009
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 7, 2010.
Original Filing: 300228073.xml
Lobbying Issues
HR 3293, House and Senate FY10 Labor-HHS Appropriations Bills (Biomedical Research & Disease Prevention Programs)
HR 3326, House and Senate FY10 DoD Appropriations Bills (Peer Reviewed Medical Research Programs)
HR 3288, Consolidated Appropriations Act of 2010
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 1030 & S 2803: Tom Lantos Pulmonary Hypertension Research and Education Act
HR 1558 & S 623: Pre-existing Condition Patient Protection Act Pulmonary Hypertension Research Prog. at NIH
HR 1085 & S 442: Health Insurance Coverage Protection Act Health Ins. Reform Legislation
HR 1708 & S 700: Ending the Medicare Disability Waiting Period Act of 2009H.R. 2866, Improving Access to Clinical Trials Act
S. 1674, Improving Access to Clinical Trials Act
H.R. 3200, America's Affordable Health Care Choices Act
S. 1679, Affordable Health Choices Act
H.R. 3962, Affordable Health Care for America Act
H.R. 3590, Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH)
3rd Quarter, 2009
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 2, 2009.
Original Filing: 300200341.xml
Lobbying Issues
House and Senate FY10 Labor-HHS Appropriations Bills (Biomedical Research and Disease Prevention Programs)
House and Senate FY10 DoD Appropriations Bills (Peer Reviewed Medical Research Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 1030: Tom Lantos Pulmonary Hypertension Research and Education Act Health Ins. Reform Legislation
HR 1558 & S 623: Pre-existing Condition Patient Protection Act Pulmonary Hypertension Research Prog. at NIH
HR 1085 & S 442: Health Insurance Coverage Protection Act
HR 1708 & S 700: Ending the Medicare Disability Waiting Period Act of 2007H.R. 2866, Improving Access to Clinical Trials Act
S. 1674, Improving Access to Clinical Trials Act
H.R. 3200, America's Affordable Health Care Choices Act
S. 1679, Affordable Health Choices Act
S., America's Health Futures Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH)
2nd Quarter, 2009
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 7, 2009.
Original Filing: 300173264.xml
Lobbying Issues
House and Senate FY10 Labor-HHS Appropriations Bills (Biomedical Research and Disease Prevention Programs)
House and Senate FY10 DoD Appropriations Bills (Peer Reviewed Medical Research Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 1030: Tom Lantos Pulmonary Hypertension Research and Education Act Health Ins. Reform Legislation
HR 1558 & S 623: Pre-existing Condition Patient Protection Act Pulmonary Hypertension Research Prog. at NIH
HR 1085 & S 442: Health Insurance Coverage Protection Act
HR 1708 & S 700: Ending the Medicare Disability Waiting Period Act of 2007
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH)
1st Quarter, 2009
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 20, 2009.
Original Filing: 300159612.xml
Lobbying Issues
House and Senate FY 10 Labor-HHS Appropriations Bills (Biomedical Research and Disease Prevention Programs)
House and Senate FY 10 DoD Appropriations Bills (Peer Reviewed Medical Research Programs)
HR 1: " American Recovery and Reinvestment Act"
HR 1105: FY 09 Omnibus Appropriations Act Charitable Giving Tax deduction proposal in President's budget
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 1030: "Tom Lantos Pulmonary Hypertension Research and Education Act"
HR 1558 / S 623: "Pre-existing Condition Patient Protection Act"
HR 1085 / S 442: "Health Insurance Coverage Protection Act"
HR 1708 / S 700: "Ending the Medicare Disability Waiting Period Act of 2009"
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
In Q4, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Jan. 16, 2009.
Original Filing: 300123204.xml
Lobbying Issues
House and Senate FY 09 Labor-HHS Appropriations Bill (Biomedical Research and Disease Prevention Programs)
House and Senate FY 09 DoD Appropriations Bills (Peer Reviewed Medical Research Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR. 3368: The "Pulmonary Hypertension Research and Education Act"
Pulmonary Hypertension Research and Education Programs through HHS
S. 3406: ADA Amendments of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
3rd Quarter, 2008
In Q3, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on Oct. 20, 2008.
Original Filing: 300103493.xml
Lobbying Issues
House and Senate FY 09 Labor-HHS Appropriations Bill (Biomedical Research and Disease Prevention Programs)
House and Senate FY 09 DoD Appropriations Bills (Peer Reviewed Medical Research Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR. 3368: The "Pulmonary Hypertension Research and Education Act"
Pulmonary Hypertension Research and Education Programs through HHS
S. 3406: ADA Amendments of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
2nd Quarter, 2008
In Q2, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on July 21, 2008.
Original Filing: 300078649.xml
Lobbying Issues
House and Senate FY 09 Labor-HHS Appropriations Bill (Biomedical Research and Disease Prevention Programs)
House and Senate FY 09 DoD Appropriations Bills (Peer Reviewed Medical Research Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
HR 493/S 358: Genetic Information Non-Discrimination legislation
HR 3368: The "Pulmonary Hypertension Research and Education Act"
Pulmonary Hypertension Research and Education Programs through HHS
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Disease Control & Prevention (CDC) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
1st Quarter, 2008
In Q1, HEALTH AND MEDICINE COUNSEL OF WASHINGTON lobbied for PULMONARY HYPERTENSION ASSOCIATION . The report was filed on April 18, 2008.
Original Filing: 300045503.xml
Lobbying Issues
FY 09 Labor-HHS Appropriations Bill (Biomedical Research and Disease Prevention Programs)
FY 09 DoD Appropriations Bills (Peer Reviewed Medical Research Programs)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH) Centers For Disease Control & Prevention (CDC)
Lobbying Issues
Medicare coverage/Reimbursement for pulmonary hypertension therapies
HR 493/S. 358: Genetic information non-discrimination legislation
HR 3368: The "Pulmonary Hypertension Research and Education Act"
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate